Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) investment case is presented by Proactive Research Analyst John Savin who explains how the company has an advantage as one of the few UK-based firms marketing an approved product into the US market.
Savin telling Proactive that Accrufer, a treatment for iron deficiency or anaemia, is a premium drug. And with Shield owning the product, this means they will take all the profit and, most importantly, control the process.